• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Fetal Surgery Increase Survival for Infants with Severe Left Diaphragmatic Hernia?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Based on observational studies, fetoscopic endoluminal tracheal occlusion (FETO) may increase survival rates among infants with severe pulmonary hypoplasia due to isolated left-sided congenital diaphragmatic hernia
    • FETO procedure: Insertion of an inflatable balloon that is removed a few weeks later | Can be  performed under local anesthesia
    • Fetal tracheal obstruction stimulates lung growth | Lung maturation following prenatal reversal of the occlusion and administration of glucocortocoids
  • Deprest et al. (NEJM, 2021) present data from a randomized controlled trial that was designed to assess whether the use of FETO results in increased postnatal survival

METHODS:

  • Open-label randomized trial
    • Tracheal Occlusion to Accelerate Lung Growth (TOTAL) trial
  • Participants
    • Singleton fetuses
    • Severe isolated congenital diaphragmatic hernia on the left side
    • Severe malformation: Observed-to-expected lung-to-head ratios of <25.0%, irrespective of liver position
  • Interventions
    • FETO at 27 to 29 weeks of gestation
    • Expectant care
  • Study design
    • A group-sequential design was used
    • Five prespecified interim analyses for superiority
    • Maximum sample size: 116 women
  • Primary outcome
    • Infant survival to discharge from the NICU

RESULTS:

  • 80 women
    • Trial was stopped early for efficacy after the third interim analysis
  • More infants in the FETO group survived to discharge
    • FETO: 40%
    • Expectant care: 15%
    • Relative risk (RR) 2.67 (95% CI, 1.22 to 6.11); P=0.009
  • Survival to 6 months of age was the same as the survival to discharge
    • RR 2.67 (95% CI, 1.22 to 6.11)
  • Women in the FETO group experienced higher incidences of
    • Preterm, prelabor rupture of membranes
      • FETO: 47%
      • Expectant care: 11%
      • RR 4.51 (95% CI, 1.83 to 11.9)
    • Preterm birth
      • FETO: 75%
      • Expectant care: 29%
      • RR 2.59 (95% CI, 1.59 to 4.52)
  • Adverse events
    • One neonatal death occurred after emergency delivery for placental laceration from fetoscopic balloon removal
    • One neonatal death occurred because of failed balloon removal (delivered at non-FETO center)
  • Analysis including 11 participants whose data was available after the RCT was stopped
    • FETO: 36%
    • Expectant care: 14%
    • RR 2.65 (95% CI, 1.21 to 6.09)

CONCLUSION:

  • The use of FETO at 27 to 29 weeks in pregnancies with isolated severe congenital diaphragmatic hernia on the left side significantly increased survival to discharge, compared to expectant management
    • This increase survival persisted to 6 months of age
  • However, FETO increased the risk of PPROM and preterm birth
  • Trial not powered for secondary outcomes such as duration of NICU stay or ventilatory support
  • The authors conclude

Because the trial involved experienced fetal surgery units, the findings should not be generalized to centers without extensive experience in fetoscopy and FETO or to centers that cannot ensure availability of a team that can perform safe and effective balloon retrieval 

Learn More – Primary Sources:

Randomized Trial of Fetal Surgery for Severe Left Diaphragmatic Hernia

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

How Does Fetoscopic Repair for Open Neural Tube Defects Compare to the Open Approach?
Can Prenatal Brain Imaging of Fetuses Undergoing Prenatal NTD Repair Predict Who will Require Postnatal Hydrocephalus Treatment?
Prenatal vs Postnatal Spina Bifida Repair and the Impact on Neurodevelopmental Impairment

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site